ROLE OF SORL1GENE AND ITS PHARMACOLOGICAL INTERACTIONS IN ALZHEIMER'S DISEASE

Abstract

Alzheimer's Disease is considered to be a remarkable global health challenge, with a crucial need for highly effective treatments. The main reason behind AD is abnormal amassing of neurofibrillary tangles and amyloid beta plaques in neurons. Among the several genetic factors implicated in AD, the SORL1 gene (Sorting Protein-Related Receptorl) or SORLA or LR11 appeared as a key player, influencing amyloid precursor protein metabolism eventually contributing to disease pathology. According to the researchers, several independent methods, including clinical pathology, human genetics, and exploratory studies in animal models, all point towards SORL1 receptor as a key player in the progression of Alzheimer's disease. This abstract focus on elucidating an effective role of gene variants of SORL1 in AD which can reduce the likelihoods of AD by synthesizing SORL1 protein. Since lipids often affect lipoprotein receptors, it has been assumed that Docosahexaenoic acid (DHA), an important ω-3 fatty acid correlated to a lower risk of Alzheimer's disease (AD) and degraded accumulation of Aß, might influence the expression of SORL1 or LR11 protein. According to the studies, DHA vividly elevate the level of SORL1 in a variety of biological systems such as mice and human neuronal cells. The interaction of DHA containing drug called Vascepa and other dementia related drugs with SORL1 protein has also been suggested to provide insights into therapeutic potential of these drugs in treatment of AD by affecting the activity of SORLI protein. Furthermore, a comprehensive comparison of binding energies of drugs with SORL1 protein receptor has been made to determine the efficacy of each drug in increasing the protein expression, eventually reducing the progression of neurodegenerative disorder. Additional research and studies need to be done on SORL1 protein to discover the possible participation in this neurodegenerative disorder.